Review




Structured Review

BioFire Defense respiratory 2.1 (rp2.1) panel
Respiratory 2.1 (Rp2.1) Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/respiratory+panel+2+1/pm40644973-120-21-27
Average 90 stars, based on 1 article reviews
respiratory 2.1 (rp2.1) panel - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Diagnostic Assay:

Article Title: APSR Annual Conference - 28 th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong.
Article Snippet: Biofire® Respiratory Panel 2.1® testing was performed on oropharyngeal and sputum samples from all patients, alongside routine clinical testing during admission.

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: Annual distribution of viral pathogens detected by the BioFire Respiratory Panel 2.1 in the pediatric (aged less than 18 years, A) and adult (aged 18 years or older, B) group from January 2020 to November 2023.

Article Title: Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.
Article Snippet: Performance characteristics of commonly used multiplex respiratory molecular panels and their clinical applications were recently reviewed in a review article by Contes and Liu [74], including BioFire Respiratory Panel 2.1, BioFire Spotfire, Roche Cobas (GenMark) ePlex respiratory pathogen panel 2 (RP2) panel, QIAstat-Dx Respiratory Panel Plus, and Luminex NxTAG Respiratory Pathogen Panel.

Article Title: Point-of-Care Multiplex Detection of Respiratory Viruses.
Article Snippet: The COVID-19 pandemic, in addition to the cooccurrence of influenza virus and respiratory syncytial virus (RSV), has emphasized the requirement for efficient and reliable multiplex diagnostic methods for respiratory infections.. While existing multiplex detection techniques are based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) and extraction and purification kits, the need for complex instrumentation and elevated cost limit their scalability and availability.. In this study, we have developed a point-of-care (POC) device based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) that can simultaneously detect four respiratory viruses (SARSCoV-2, Influenza A, Influenza B, and RSV) and perform two controls in less than 30 min, while avoiding the use of the RNA extraction kit.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in compari son to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in comparison to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era.
Article Snippet: With the emergence of SARS-CoV-2, respiratory panels for diagnostic testing were altered to include SARS-CoV-2, one being the BioFire Respiratory Panel 2.1 [12].

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: We also observed the prevalence (Table 3) of each age group among positive samples detected by the BioFire Respiratory Panel 2.1.

Multiplex Assay:

Article Title: APSR Annual Conference - 28 th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong.
Article Snippet: Biofire® Respiratory Panel 2.1® testing was performed on oropharyngeal and sputum samples from all patients, alongside routine clinical testing during admission.

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: Annual distribution of viral pathogens detected by the BioFire Respiratory Panel 2.1 in the pediatric (aged less than 18 years, A) and adult (aged 18 years or older, B) group from January 2020 to November 2023.

Article Title: Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.
Article Snippet: Performance characteristics of commonly used multiplex respiratory molecular panels and their clinical applications were recently reviewed in a review article by Contes and Liu [74], including BioFire Respiratory Panel 2.1, BioFire Spotfire, Roche Cobas (GenMark) ePlex respiratory pathogen panel 2 (RP2) panel, QIAstat-Dx Respiratory Panel Plus, and Luminex NxTAG Respiratory Pathogen Panel.

Article Title: Point-of-Care Multiplex Detection of Respiratory Viruses.
Article Snippet: The COVID-19 pandemic, in addition to the cooccurrence of influenza virus and respiratory syncytial virus (RSV), has emphasized the requirement for efficient and reliable multiplex diagnostic methods for respiratory infections.. While existing multiplex detection techniques are based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) and extraction and purification kits, the need for complex instrumentation and elevated cost limit their scalability and availability.. In this study, we have developed a point-of-care (POC) device based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) that can simultaneously detect four respiratory viruses (SARSCoV-2, Influenza A, Influenza B, and RSV) and perform two controls in less than 30 min, while avoiding the use of the RNA extraction kit.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in compari son to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in comparison to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era.
Article Snippet: With the emergence of SARS-CoV-2, respiratory panels for diagnostic testing were altered to include SARS-CoV-2, one being the BioFire Respiratory Panel 2.1 [12].

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: We also observed the prevalence (Table 3) of each age group among positive samples detected by the BioFire Respiratory Panel 2.1.

Polymerase Chain Reaction:

Article Title: APSR Annual Conference - 28 th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong.
Article Snippet: Biofire® Respiratory Panel 2.1® testing was performed on oropharyngeal and sputum samples from all patients, alongside routine clinical testing during admission.

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: Annual distribution of viral pathogens detected by the BioFire Respiratory Panel 2.1 in the pediatric (aged less than 18 years, A) and adult (aged 18 years or older, B) group from January 2020 to November 2023.

Article Title: Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.
Article Snippet: Performance characteristics of commonly used multiplex respiratory molecular panels and their clinical applications were recently reviewed in a review article by Contes and Liu [74], including BioFire Respiratory Panel 2.1, BioFire Spotfire, Roche Cobas (GenMark) ePlex respiratory pathogen panel 2 (RP2) panel, QIAstat-Dx Respiratory Panel Plus, and Luminex NxTAG Respiratory Pathogen Panel.

Article Title: Point-of-Care Multiplex Detection of Respiratory Viruses.
Article Snippet: The COVID-19 pandemic, in addition to the cooccurrence of influenza virus and respiratory syncytial virus (RSV), has emphasized the requirement for efficient and reliable multiplex diagnostic methods for respiratory infections.. While existing multiplex detection techniques are based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) and extraction and purification kits, the need for complex instrumentation and elevated cost limit their scalability and availability.. In this study, we have developed a point-of-care (POC) device based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) that can simultaneously detect four respiratory viruses (SARSCoV-2, Influenza A, Influenza B, and RSV) and perform two controls in less than 30 min, while avoiding the use of the RNA extraction kit.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in compari son to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in comparison to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era.
Article Snippet: With the emergence of SARS-CoV-2, respiratory panels for diagnostic testing were altered to include SARS-CoV-2, one being the BioFire Respiratory Panel 2.1 [12].

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: We also observed the prevalence (Table 3) of each age group among positive samples detected by the BioFire Respiratory Panel 2.1.

Virus:

Article Title: APSR Annual Conference - 28 th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong.
Article Snippet: Biofire® Respiratory Panel 2.1® testing was performed on oropharyngeal and sputum samples from all patients, alongside routine clinical testing during admission.

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: Annual distribution of viral pathogens detected by the BioFire Respiratory Panel 2.1 in the pediatric (aged less than 18 years, A) and adult (aged 18 years or older, B) group from January 2020 to November 2023.

Article Title: Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.
Article Snippet: Performance characteristics of commonly used multiplex respiratory molecular panels and their clinical applications were recently reviewed in a review article by Contes and Liu [74], including BioFire Respiratory Panel 2.1, BioFire Spotfire, Roche Cobas (GenMark) ePlex respiratory pathogen panel 2 (RP2) panel, QIAstat-Dx Respiratory Panel Plus, and Luminex NxTAG Respiratory Pathogen Panel.

Article Title: Point-of-Care Multiplex Detection of Respiratory Viruses.
Article Snippet: The COVID-19 pandemic, in addition to the cooccurrence of influenza virus and respiratory syncytial virus (RSV), has emphasized the requirement for efficient and reliable multiplex diagnostic methods for respiratory infections.. While existing multiplex detection techniques are based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) and extraction and purification kits, the need for complex instrumentation and elevated cost limit their scalability and availability.. In this study, we have developed a point-of-care (POC) device based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) that can simultaneously detect four respiratory viruses (SARSCoV-2, Influenza A, Influenza B, and RSV) and perform two controls in less than 30 min, while avoiding the use of the RNA extraction kit.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in compari son to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in comparison to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era.
Article Snippet: With the emergence of SARS-CoV-2, respiratory panels for diagnostic testing were altered to include SARS-CoV-2, one being the BioFire Respiratory Panel 2.1 [12].

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: We also observed the prevalence (Table 3) of each age group among positive samples detected by the BioFire Respiratory Panel 2.1.

Bacteria:

Article Title: APSR Annual Conference - 28 th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong.
Article Snippet: Biofire® Respiratory Panel 2.1® testing was performed on oropharyngeal and sputum samples from all patients, alongside routine clinical testing during admission.

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: Annual distribution of viral pathogens detected by the BioFire Respiratory Panel 2.1 in the pediatric (aged less than 18 years, A) and adult (aged 18 years or older, B) group from January 2020 to November 2023.

Article Title: Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.
Article Snippet: Performance characteristics of commonly used multiplex respiratory molecular panels and their clinical applications were recently reviewed in a review article by Contes and Liu [74], including BioFire Respiratory Panel 2.1, BioFire Spotfire, Roche Cobas (GenMark) ePlex respiratory pathogen panel 2 (RP2) panel, QIAstat-Dx Respiratory Panel Plus, and Luminex NxTAG Respiratory Pathogen Panel.

Article Title: Point-of-Care Multiplex Detection of Respiratory Viruses.
Article Snippet: The COVID-19 pandemic, in addition to the cooccurrence of influenza virus and respiratory syncytial virus (RSV), has emphasized the requirement for efficient and reliable multiplex diagnostic methods for respiratory infections.. While existing multiplex detection techniques are based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) and extraction and purification kits, the need for complex instrumentation and elevated cost limit their scalability and availability.. In this study, we have developed a point-of-care (POC) device based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) that can simultaneously detect four respiratory viruses (SARSCoV-2, Influenza A, Influenza B, and RSV) and perform two controls in less than 30 min, while avoiding the use of the RNA extraction kit.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in compari son to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs
Article Snippet: Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 plus for detection of SARS-CoV-2 in 3,750 anterior nasal swab (NS) specimens and nasopharyngeal swab (NPS) from 32 sites in comparison to the FDA-authorized BioFire Respiratory Panel 2.1.

Article Title: Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era.
Article Snippet: With the emergence of SARS-CoV-2, respiratory panels for diagnostic testing were altered to include SARS-CoV-2, one being the BioFire Respiratory Panel 2.1 [12].

Article Title: Unveiling the dynamics of respiratory infections revealed by multiplex PCR testing during the COVID-19 pandemic in Taiwan, 2020-2023.
Article Snippet: We also observed the prevalence (Table 3) of each age group among positive samples detected by the BioFire Respiratory Panel 2.1.



Similar Products

94
ZeptoMetrix corporation nattroltm respiratory panel 2 1
Nattroltm Respiratory Panel 2 1, supplied by ZeptoMetrix corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/NATtrol+Respiratory+Panel+2%2E1/med_rxiv__64898__2026__03__05__26347454-69-10-14
Average 94 stars, based on 1 article reviews
nattroltm respiratory panel 2 1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
ZeptoMetrix corporation nattrol respiratory verification panel 2 1
Nattrol Respiratory Verification Panel 2 1, supplied by ZeptoMetrix corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/NATtrol+Respiratory+Verification+Panel/pmc12844171-237-3-8
Average 93 stars, based on 1 article reviews
nattrol respiratory verification panel 2 1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
ZeptoMetrix corporation nattrol respiratory panel 2⋅1
Nattrol Respiratory Panel 2⋅1, supplied by ZeptoMetrix corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/NATtrol+Respiratory+Panel+2%2E1/pm41045941-58-51-55
Average 94 stars, based on 1 article reviews
nattrol respiratory panel 2⋅1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
BioFire Defense respiratory 2.1 (rp2.1) panel
Respiratory 2.1 (Rp2.1) Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/respiratory+panel+2+1/pm40644973-120-21-27
Average 90 stars, based on 1 article reviews
respiratory 2.1 (rp2.1) panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioFire Defense respiratory 2.1 panel
Respiratory 2.1 Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/respiratory+panel+2+1/pm40662583-108-16-18
Average 90 stars, based on 1 article reviews
respiratory 2.1 panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioFire Defense filmarray respiratory panel 2.1
Filmarray Respiratory Panel 2.1, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/filmarray+respiratory+panel/pm40573450-1-34-33
Average 90 stars, based on 1 article reviews
filmarray respiratory panel 2.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioFire Defense multiplex pcr biofire filmarray respiratory panel 2.1 plus kit
Multiplex Pcr Biofire Filmarray Respiratory Panel 2.1 Plus Kit, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/biofire+respiratory+panel/pm40503876-60-1-3
Average 90 stars, based on 1 article reviews
multiplex pcr biofire filmarray respiratory panel 2.1 plus kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
bioMerieux gmbh respiratory 2.1 panel rp2.1
Respiratory 2.1 Panel Rp2.1, supplied by bioMerieux gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/respiratory+2+1+panel+rp2+1/pm40431685-27-39-43
Average 90 stars, based on 1 article reviews
respiratory 2.1 panel rp2.1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioFire Defense filmarray® biofire® rp 2.1 plus multiplex respiratory panel
Filmarray® Biofire® Rp 2.1 Plus Multiplex Respiratory Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2%2E1/biofire+respiratory+panel/pm40314504-1314-24-25
Average 90 stars, based on 1 article reviews
filmarray® biofire® rp 2.1 plus multiplex respiratory panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results